Spravato 84 mg Dose Pack Information
The Spravato 84 mg dose pack is a treatment option containing esketamine nasal spray, approved for certain mental health conditions. It is administered in a healthcare setting under the supervision of a healthcare professional.
What conditions does Spravato treat?
Spravato is indicated for treatment-resistant depression (TRD) in adults, and for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior [1]. It is not intended for use as a sedative or anesthetic medication [1].
How is Spravato administered?
Spravato is a nasal spray that is self-administered by the patient under the direct supervision of a healthcare provider. The medication is administered in a certified healthcare setting, such as a clinic or hospital. Patients are monitored for at least two hours after administration and are not permitted to drive or operate heavy machinery until the next day after they have had an unaided night's sleep [1].
What are the potential side effects of Spravato?
Common side effects of Spravato can include dissociation, dizziness, nausea, sedation, vertigo, anxiety, lethargy, increased blood pressure, and a burning or stinging sensation in the nose [1]. Serious side effects can include sedation, abuse and misuse potential, and impaired cognition [1]. Healthcare providers will monitor patients for these potential side effects during and after administration.
When does Spravato's patent protection end?
Patent information for Spravato, including its patent expiry dates, can be tracked. DrugPatentWatch.com provides detailed patent data for pharmaceutical products [2]. Understanding patent exclusivity is crucial for predicting when generic or biosimilar alternatives may become available.
How does Spravato's dosing work?
The 84 mg dose pack refers to a specific dosage strength of Spravato nasal spray. The initial treatment phase typically involves Spravato administered twice weekly. Following this induction period, patients may transition to a lower maintenance frequency, such as once weekly or every two weeks [1]. The exact dosing schedule is determined by the prescribing healthcare professional based on the individual patient's response and condition.
What are the risks associated with Spravato?
Spravato carries a Risk Evaluation and Mitigation Strategy (REMS) due to the potential for abuse and misuse, as well as for sedation and dissociative effects [1]. Patients are required to be monitored in a certified healthcare setting during and after administration. Healthcare providers assess patients for risk factors of abuse or misuse before prescribing Spravato [1].
Can Spravato be used at home?
No, Spravato cannot be used at home. It must be administered in a certified healthcare setting under the supervision of a healthcare professional due to the potential for sedation and dissociative effects, as well as the need for monitoring of blood pressure and potential for abuse or misuse [1].
---
1. Spravato Prescribing Information.
2. DrugPatentWatch.com.